Humacyte, Inc. Common Stock
Here’s whether Humacyte, Inc. Common Stock (HUMA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 46 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-16.75% over 10 days); weak 1-year return of -58.3%; 3-month momentum negative (-38.8%); rising volume on a downtrend (distribution, 1.87x avg). Currently 74.8% off its 52-week high. Score: -5/7.
HUMA is trading below its 200-day MA ($0.97) — a key warning sign the longer-term trend is under pressure. An RSI of 46.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -58.3% compares to +20.5% for SPY (trailed the market by 78.8%). The current 74.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.